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Premenopausal women are relatively protected against the development of
coronary heart disease, when compared with age-matched men. This difference dissolves
after menopause and is accepted to be hormonally mediated. Despite recent clinical
controversies in the use of hormone replacement therapy in postmenopausal women,
there have been numerous in vitro and in vivo studies that demonstrate favorable effects
of estrogen on the endothelium. The Bender laboratory has shown that 17|3-estradiol (E2)
rapidly induces nitric oxide (NO) release from human endothelial cells (EC) in vitro.
This occurs through a c-Src/phosphatidylinositol 3-kinase (PI3-kinase)/Akt pathway, in a
rapid fashion in the absence of modulated gene expression. In addressing how these
membrane growth factor receptor-type responses to a steroid hormone could occur, the
Bender laboratory also demonstrated that EC have more than one form for ERa. The
classical ERa, a 66kDa protein, is predominantly cytosolic and nuclear, and comprises a
minority of the ERs in most EC. ER46, a 46kDa protein, is a product of an alternative
transcript splice form, and represents a majority of the ERs in most EC. ER46 has a
predilection for membrane targeting, and more efficiently transduces the favorable EC
activation responses to E2 described above. Given the controversy surrounding the
effects of hormone replacement therapy in postmenopausal women, the design and use of
selective estrogen receptor modulators (SERMs) has recently gained great attention and
hope that some of these compounds will have beneficial effects on vascular and bone
cells, without the detrimental side/toxic effects.
The hypothesis is that, of a selected panel of potential SERMs, there will be a
hierarchy of efficacy and toxicity, with regard to rapid induction of endothelial nitric
oxide synthase (eNOS) activation through EC membrane ER46, and to proliferative
responses of breast cancer cells, respectively. A compound that is found to be highly
efficient at inducing eNOS activation, and minimally pro-proliferative, may be a
tremendously useful prophylactic and threapeutic agent in humans.
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As early as the 1950s, animal studies have shown that exogenous estrogen could
inhibit coronary atherosclerosis, when it was observed that estrogen inhibited coronary
atherosclerosis in cholesterol fed chicks (1). Studies by Harder and Coulson in the late
1970s (2) showed that estrogen binds to coronary artery smooth muscle cells in a canine
model. In the early 1990's, Williams et al. (3) performed a number of studies of
estrogen's effects in female cynomolgus monkeys. The initial studies performed in
ovariectomized females demonstrated that long-term estrogen treatment improved
vasomotor function and reduced atherosclerosis. It was not clear, however, whether this
was a direct vascular effect or an effect mediated via changes in circulating lipoproteins.
Williams et al. (4) later attempted to determine the effects of short term estrogen
administration on the vascular responses of atherosclerotic arteries in ovariectomized
cynomolgus monkeys. The vascular responses of coronary arteries to the endothelium-
mediated vasodilator acetylcholine were reversed from abnormal vasoconstriction to
vasodilation within 20 minutes after an infusion of ethinyl estradiol. This reversal was
not accompanied by any changes in plasma cholesterol levels, demonstrating a direct
effect of estrogen on the vascular endothelium.
Even though the cardioprotective effects of estrogen in women are believed to be
mediated, in part, by its effects on lipoprotein levels, the studies by Williams et al (4)
support the importance of direct effects of estrogen on the vasculature. Since then, studies
have helped to further elucidate the cardiovascular effects of hormone replacement
therapy (HRT) and the importance of timing of therapy initiation.
2.0 Effects of Estrogen on Vascular Endothelium Function
Vascular endothelial cells play an important role in modulating the tone of the
underlying vascular smooth muscle by the synthesis and release of vasodilator factors
such as NO, prostacyclin, endothelium derived hyperpolarizing factor, and
vasoconstrictor factors such as PGH2, endothelin, and oxygen derived free radicals, as

















- Direct Effects of Estrogen on Blood Vessels (From Haynes et al., Rapid vascular
cell responses to estrogen and membrane receptors, Vascul. Pharmacol. 38 (2002), pp. 99-108)
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2.1 Up-regulation of Endothelial Nitric Oxide (eNO) Production
Early studies indicated the possible influence of sex steroid hormones on eNO
synthesis by demonstrating gender differences in endothelium-dependent modulation of
vascular tone (6-8). Studies on isolated rat aorta showed that the vascular endothelium of
female WKY rats is capable of producing larger amounts of NO under both basal and
stimulated conditions than that of male WKY rats (9). Further studies investigating the
effect of ovariectomy and/or estrogen treatment on endothelium-dependent vascular
responses supported the hypothesis that the greater production of eNO in females is due
to the effect of the female sex steroid hormone (17P-estradiol) (8,10,11). Gisclard et al.
(1-6) described increased endothelium dependent relaxation in isolated femoral arteries of
rabbits after 4 days of treatment with 17P-estradiol. Hayashi et al. 1-4 showed that basal
release of NO from female rabbit aorta was greater than that from male or ovariectomized
female rabbit aortas.
Clinical investigations have also demonstrated attenuation of abnormal vasomotor
responses by administration of ethinyl-estradiol (12) or physiological doses of 17(3-
estradiol (13). A two year follow up study reported increases in circulating NO levels in
postmenopausal women on HRT compared to women not taking estrogen (13).
2.2 Mechanisms Involved in Estrogen Mediated Increased eNO Production
2.2.1 Genomic Effects
The longer-term effects of estrogen are produced, at least in part, by changes in
vascular cell gene and protein expression. These effects are mediated by ligand activated
transcription factors, estrogen receptors ER-a and ER-(3, which are members of the
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nuclear hormone receptor superfamily. Although both ER-a and ER-P are expressed in
endothelial (14) and vascular smooth muscle cells (15,16), some data show that ER-P
expression predominates in endothelial cells, whereas ER-a expression is greater
in
smooth muscle cells. When estrogen binds to its receptors (see Figure 2), the estrogen-
ER complexes undergo homodimerization or heterodimerization, (17) after which they
are able to bind specific DNA sequences in the control regions of their target genes and
upregulate transcription of these genes. The estrogen-ER complex interacts with several
Figure 2 - Mechanism of Estrogen-Receptor Activation of Gene Expression. The signal
transduction pathways available to estrogen or a selective estrogen receptor modulator (SERM) to initiate
gene transcription. Estrogen binds to either estrogen receptor ER-a or ER-(3 and subsequently binds
coactivator (CoA) molecules required to form a transcription complex at an estrogen response element
(ERE) located in the promoter region of an estrogen-responsive gene. The antiestrogenic action of a SERM
results from the inappropriate folding of an ER-a or ER-(3 complex that either cannot recruit CoA
molecules or instead recruits corepressor (CoR) molecules. This programmed change in conformation
produces antiestrogen action at specific sites like the breast but estrogen-like effects in the uterus if an
excess of CoA molecules is present. These events modulate gene transcription through EREs. SERM-ER
complexes may also initiate gene transcription to produce an estrogen-like effect, by forming a protein-
protein interaction at fos/jun that activates activating protein (AP)-l sites. In addition, SERMs may produce
nongenomic effects and alter tissue biochemistry without interacting with ERs (From Jordan et al., Journal
of the National Cancer Institute, 2001, Vol. 93, NO 19, 1449-1457).
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proteins that are recruited to the receptor after ligand binding and facilitate transcriptional
activation. These ER associated proteins have the ability to further recruit transcription
proteins, and in some cases have enzymatic functions that facilitate target gene
expression (18). Control of gene expression by the estrogen-ER complexes, thus,
involves a series of specific molecular interactions among estrogens, ERs, ER-associated
proteins, and the precise control regions for the estrogen target genes present in a given
cell.
ERs in vascular cells alter the expression of a number of such specific target
genes (see Table 1). Important examples of such genes in the cardiovascular system
include: prostacyclin cyclooxygenase, prostacyclin synthase, endothelial nitric oxide
synthase, inducible nitric oxide synthase, endothelin- 1, collagen, matrix
metalloproteinase, vascular cell adhesion molecules, vascular endothelial growth factor,
elastin, and progesterone receptor (16). The protein products of these genes, in turn, are
thought to mediate specific genomic effects of estrogen on vascular tissue in an autocrine
and/or paracrine manner (19). Even though ERs are by all evidence to date identical,
regardless of where they are expressed, it is thought that the receptor associated proteins
that are recruited after ligand binding provide a first level of specificity leading to cell
specific events. These coactivator/repressor proteins may be expressed in different ratios
in various cell types, and may also assemble in unique combinations that allow for a
certain degree of specificity. Additional cell specific ER associated coactivator or
coregulatory proteins may also exist (20). These tissue-specific or cell-specific ER-
associated coactivator proteins represent attractive targets for drug discovery.
A second level of target tissue specificity is likely provided by cis-acting elements
specific to the genes that are regulated by estrogen in a given cell. For example, the gene
for eNOS is upregulated by estrogen in vascular cells but not in bone or reproductive
tissues (19). This means that the genes activated by estrogen in vascular cells are
different from those activated in bone cells, and the regulatory regions of these genes
likely dictate some of the specificity of a gene in a given cellular environment.
Table 1. EsmoGKN-REGUi-vren Genus or Potential Importance





Endothelial nitric oxide synthase






Vascular endothelial growth factor
Candidate estrogen -regulated genes
(nonvascular cells)
Growth- and development -related genes
Transforming growth Kictor fi^2*
Epidermal growth factor receptor
Platelet-derived growth factor25
tit 4 tyrosine kinase









Signaling-related and miscellaneous genes
Estrogen receptor a
Estrogen receptor fl
Monocyte chcmotactic protein I29
lsiL and HK2 (cardiac potassium channels)30
Connexin 43
Leptin"
Apolipoprotcins A, B, D, and E and Lp(a)
Angiotcnsin-convcrring enzyme
Angiotensin II receptor, type I
Physiologic or Pathophysiologic Role*
Vasodilatation
Vasodilatation






Angkigcncsis and cndothclial-ccll proliferation
Wound healing
Cell growth in response to vascular injury
Cell growth in response to vascular injury
Angiogcncsis and cndothclial-ccll prolitcratio
Hcmostasis in response to thrombosis
Hcmostasis in response to thrombosis
Hcmostasis in response to thrombosis
Hcmostasis in response to thrombosis
Hcmostasis in response to thrombosis
Hcmostasis in response to thrombosis
Fibrinolysis
Anticoagulation
Hormonal regulation and gene expression
Hormonal regulation and gene expression
Monocyte recruitment and atherosclerosis
Cardiac conduction
Cardiac conduction
Fat metabolism and obesity
Lipid metabolism and atherosclerosis
Vasoconstriction
Vasoconstriction
Table 1- Estrogen-Regulated Genes of Potential Importance in Vascular Physiology
and Disease. (From Mendelsohn et al., The Protective Effects of Estrogen on the Cardiovascular System
NEngl J Med 1999 340: 1801-1811)
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Approximately a third of the protective cardiovascular effects of estrogen can be
attributed to modification of known risk factors by estrogen, such as modulation of the
levels or activities of lipoproteins and apoproteins and of coagulation and fibrinolytic
proteins. These effects are primarily those of estrogen on ER-a in hepatic cells (19).
2.2.2 Nongenomic Effects
Estrogen can increase the bioavailability of eNO in a variety of models (19,20).
Administered directly into the coronary artery of a nonhuman primate or a human,
estradiol causes rapid vasodilation by a activating eNO production (19).
The molecular mechanisms by which estrogen activates eNOS is currently an area
of active interest. In 1997 Lantin-Hermoso et al. (22) and Caulin-Glaser et al. (21)
reported that relatively specific antagonists of the ERs could inhibit nitric oxide release
form cultured endothelial cells exposed to physiologic concentrations of estrogen.
Lantin-Hermoso et al. (22) demonstrated that eNOS activity increased in a dose
dependent manner within 5 minutes after ovine pulmonary artery endothelial cells were
exposed to 17(3-estradiol. In these studies, removal of ionic calcium completely inhibited
eNOS activity stimulated by 17P-estradiol. This supported the hypothesis that 17(3-
estradiol acutely stimulates eNOS by increasing calcium influx. The ER antagonist ICI-
182780 fully inhibited eNOS activity stimulated by 17P-estradiol in these studies.
Caulin-Glaser et al (21) demonstrated a rapid increase in nitric oxide release from
endothelial cells form the female human umbilical vein in response to 17P-estradiol.
Similarly, they found that the ER antagonist ICI 164,384 inhibited this increase in nitric
oxide release.
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In 1999, Chen et al. (23) showed that ER-a can mediate the short term effects of
estrogen on eNOS activity. 17p-estradiol causes activation of eNOS within 5 minutes.
This activation was specific to 17P-estradiol, required the ER-a hormone binding domain,
and was blocked by ER antagonists. The acute response of eNOS to 17P-estradiol could
be reconstituted in COS cells cotransfected with ER-a and eNOS, but not in those
transfected with eNOS alone. Additionally, 17P-estradiol caused the rapid, ER-
dependent activation of the mitogen-acivated protein (MAP) kinase, and the MAP kinase
inhibitor PD-98059 blocked the ability of 17P-estradiol to activate eNOS in intact
endothelial cells. These findings suggested that the rapid activation of eNOS is mediated
by ER-a functioning in a nongenomic way. The data from this study also suggest that the
MAP kinase pathway might be recruited by activation of ER and be involved in eNOS
activation.
In 2000 Haynes et al. (24) provided evidence for the involvement of a second
signal transduction pathway in eNOS activation, and demonstrated that PI 3-kinase is
capable of activating Akt (protein B kinase, a serine/threonine kinase down-stream of PI
3-kinase). Akt, in turn, directly phosphorylated and activated eNOS. Simonicini et al.
(25) showed that human recombinant ER-a binds in a ligand-dependent manner to the
p85a regulatory subunit of PI 3-kinase. Stimulation with estrogen increased ER-a
associated PI 3-kinase activity, leading to activation of Akt and eNOS. Chambliss et al.
(26) also reported in 2000 that the ER-eNOS signaling system is localized to endothelial
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Figure 3 - Signal Transduction Pathway in eNOS Activation. (From Kim et al., Rapid,
Estrogen Receptor-Mediated Signaling: Why Is the Endothelium So Special? Sci. STKE 2005 (288),
pe28.)
3.0 The Effect of Increased Endothelial Nitric Oxide Production in the Anti-
Atherosclerotic and Antihypertensive Effects of 17p-estradiol.
3.1 Atherosclerosis
Endothelial cell injury or endothelial dysfunction is considered to play an
important role in the development of atherosclerotic lesions (27,28). One of the
manifestations of endothelial cell dysfunction is an impairment or reduction of NO
production. In 1990, Williams et al. (29) suggested that the vasodilatory effect of
estrogen may be mediated by increased NO production by showing enhanced
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acetylcholine-induced, endothelium-dependent relaxation of coronary arteries following
17P-estradiol treatment of cholesterol-fed cynomolgus monkeys. Chronic inhibition of
NO formation accelerated atherosclerotic progression in hypercholesterolemic rabbits
(30,31) and apolipoprtotein E deficient mice (32), further supporting the role of increased
eNO production in mediating the anti-atherosclerotic effect of 17p-estradiol.
In 1999 Nascimento et al. (33) investigated the role of NO in mediating the
protective effect of 17P-estradiol on atherosclerotic lesion development in
ovariectomized, hypercholesterolemic rabbits. Their results showed diminished aortic
lesion formation in the estrogen-treated animals accompanied by enhanced endothelium-
dependent vasorelaxation of isolated aortic rings, suggesting that the anti-atherosclerotic
effect of 17P-estradiol could be mediated, at least in part, by increased NO formation in
the aortic endothelium. In the same study chronic, systemic administration of L-NAME
to 17P-estradiol-treated hypercholesterolemic rabbits significantly attenuated the anti-
atherosclerotic effects of estrogen. Similarly, Holm et al. (34) reported that long-term
inhibition of NO synthesis by L-NAME significantly reduced the anti-atherogenic effect
of 17P-estradiol and levormeloxifene, a partial estrogen receptor agonist. Levels of
plasma cholesterol were fixed, thus demonstrating that the beneficial effect of estrogens
in this model is dependent on eNO production and independent of plasma cholesterol
lowering. The results of these experiments demonstrate a strong correlation between
elevated NO production and anti-atherosclerotic effects of estrogen in this model.
However, other factors may also be involved that are able to mediate estrogen-induced
protection against atherosclerotic plaque development, including inhibition of VCAM-1
up-regulation and monocyte extravasation (34).
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3.2 Hypertension
It has been shown that women of reproductive age are less prone to hypertension
and hypertension-related diseases than men or postmenopausal women (34). Studies by
Winber et al. in 1995 (35) using 24-h ambulatory blood pressure monitoring showed that
blood pressure is higher in men than in women at similar ages. These gender-associated
differences in blood pressure observed in humans have also been documented in
hypertensive animal models. It has been shown that male spontaneously hypertensive
rats (SHR) (36), male Dahl salt-sensitive (DS) rats (37) and male deoxycorticosterone-
salt hypertensive rats (38) have higher blood pressure than their females counterparts.
The important role of ovarian steroid hormones in blood pressure regulation is further
supported by the observation that blood pressure increases after menopause in individuals
(39). Reducing estrogen levels by ovariectomy aggravates hypertension in DS rats (40),
and estrogen replacement has been shown to decrease blood pressure in postmenopausal
women (41).
One possible mechanism that may explain the antihypertensive effect of 17P-
estradiol is augmentation of endothelial NO production. The aorta of female SHR
produces more NO than that of male SHR, and 17p-Estradiol increases eNO mediated
vasodilation in female hypertensive rats (42). These studies in rats have been confirmed
by clinical investigations, demonstrating attenuation of abnormal vasomotor responses by
administration of ethinyl-estradiol (44) or by physiological doses of 17p-estradiol (45).
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4.0 The Effects of Estrogen on Angiogenesis
4.1 Angiogenesis Related to Ovulation and Pregnancy
The majority of angiogenesis seen in mammals occurs during embryogenesis.
Adult animals demonstrate a down-regulation of angiogenic responses compared to
developing embryos under nonpathological conditions. The exceptions are found in
females where during the maturation of the ovarian follicle, the priming of the
endometrium for implantation and development of the embryo, adult angiogenesis is
essential (46-50). During the menstrual cycle, increased estrogen production and
angiogenesis are temporally related (51). The preovulatory surge in circulating 17P-
estradiol plasma level is accompanied by a high degree of angiogenic activity (52). In the
rat ovary, rapidly dividing endothelial cells produce vessels to support the developing
corpus luteum (53). Rapid angiogenesis just after the estrogen surge produces the coiled
arteries of the endometrium (54). On the other hand, withdrawal of estrogen in cattle
induces rapid vessels regression (47). These studies suggest that ovarian steroid
hormones, such as 17p-estradiol, may stimulate angiogenesis.
4.2 17p-estradiol Promotes Angiogenesis
Injury to the vessel wall or disruption of the basement membrane that surrounds
the capillaries leads to activation of endothelial cells. The cells secrete extracellular
matrix proteases, permitting them to migrate into the stromal space and to attach to other
matrix molecules. Proliferation yields a sufficient mass of cells to permit organization
13
into new tubular structures. With secretion and remodeling of a new basement membrane,
and attachment of pericytes, a mature capillary is formed (55).
In 1995 Morales et al. (56) showed that estradiol promotes new vessel formation
both in vitro and in vivo. When endothelial cells are plated on a layer of basement
membrane matrix (Matrigel), the cells attach, migrate and form tube-like structures with a
lumen (57). This morphological differentiation mimics some of the steps involved in
angiogenesis in situ. This observation suggested that angiogenesis in vivo might also be
controlled by estradiol. Morales and colleagues employed a model in which PFGF, mixed
into the basement membrane extract Matrigel, is injected subcutaneously in mice.
Matrigel is a liquid at 4 °C but polymerizes at 37 °C to form scaffolding that is subject to
vascular invasion and can be removed subsequently for analysis. Without PFGF, little
endothelial cell invasion is observed after 7 days. However, when PFGF is added to the
Matrigel, there is marked invasion of cellular elements that are almost entirely von
Willebrand factor-positive. Organized vessels are present and contain erythrocytes. If
mice are subjected to ovariectomy 2 weeks before implanting the Matrigel plug, there is a
marked reduction in cellular invasion to the plug, which is restored by estrogen treatment
(56).
Estrogen has also been suggested to be proangiogenic in ischemic tissues since
intramuscular injection of the ovarian steroid hormone significantly increased collateral
vessel formation in a rabbit hind-limb ischemia model (58).
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4.3 Potential Mechanisms Involved in the Proangiogenic Effect of Estrogen
The mechanisms involved in the proangiogenic effects of estrogen are
multifactorial and include up-regulation of expression of both VEGF and its receptors
(59-63), pFGF (64), augmentation of NO synthesis (65), induction of expression of
vascular adhesion molecules (66) and integrins (67,68), and inhibiting endothelial cell
apoptosis (69,70). The surface expression of integrins pi, a5 and a6 on endothelial cells
is regulated by estradiol. Estradiol has a direct effect and does not require the presence of
inflammatory cytokines. Since integrins have an important role in mediating endothelial
cell attachment, migration, growth and differentiation (67), the increase in integrin
expression and function may be an important mechanism by which estrogen regulates
angiogenesis.
Estrogen stimulates VEGF production in rats (63), monkeys and humans (59).
These studies indicate that at least one mechanism by which estrogen may stimulate
angiogenesis is through up-regulation of expression of VEGF and VEGF receptors.
However, the angiogenic effects of estrogen are not limited to the tissues important for
reproductive biology, nor are they mediated only by VEGF. In 1991, Schecter and
Weiner (68) reported that estrogen induces PFGF production by gonadotropic cells in the
periphery of the pituitary in Fischer 344 rats. These peripheral sites were adjacent to
areas of increased capillary formation required to support ongoing glandular hypertrophy.
5.0 Estrogen and Breast Cancer
Estrogen, in addition to other hormones, has an essential role in the development
of the female sex organs, the secondary sex characteristics, the regulation of the
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menstrual cycle and reproduction. Therefore, it has been proposed that the effects of
many well-established reproductive risk factors for breast cancer are mediated by
hormonal mechanisms, for the most part involving estrogens (71).
One of the major concerns about the use of long-term HRT is the link between
estrogen and the development of breast cancer. Epidemiological and experimental
evidence implicates estrogens in the etiology of breast cancer, and most established risk
factors for breast cancer in humans are thought to influence risk through hormone-related
pathways (71). Increased concentrations of endogenous estrogens are strongly associated
with increased risk for breast cancer in postmenopausal women (72), and trials have
shown that the anti -estrogens tamoxifen and raloxifene reduce the incidence of breast
cancer (73). In an analysis of 51 studies, the relative risk of breast cancer was 1.35 (95%
confidence interval = 1.21 to 1.49) for women who currently or recently (i.e., within the
past 4 years) used HRT for 5 years or more (74). In the Breast Cancer Detection and
Demonstration Project, the risk of breast cancer increased by 8% per year of HRT (75).
However, the effects of estrogen alone do not fully account for the relationships observed
between breast cancer and hormone-related risk factors. Other hormones, such as
progesterone (71), prolactin (76), and testosterone (77), may also be important.
5.1 Proliferative Effects of Estrogen on Breast Tissue
Estrogen has been shown to have a marked proliferative effect on breast epithelial tissue
in model systems (78). Both endogenous and exogenous estrogens stimulate breast
epithelial cell mitosis, increasing the number of cell divisions and thus the opportunity for
random genetic errors (71,79). Estrogen concentrations may be important at all stages in
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the development of breast neoplasms because the hormonal stimulus to cell division
continues all along the progression pathway (80). The proliferative effects of estrogens
are brought about on entering target cells, where they bind with a receptor protein, which
then binds to hormone response elements on the nuclear DNA, activating or suppressing
specific sequences in the regulatory regions of genes responsive to estrogen that control
cell growth and differentiation (81).
It has also been suggested that estrogens might have an important influence on
risk for developing breast cancer through effects before the initiation of the disease (82).
Elevated estrogen levels during fetal life have been shown to influence morphology of
the mammary gland (83), and are also thought to be responsible for the persistence of
epithelial structures (terminal end buds) that are known to be sites of malignant
transformation (84). Results from animal models and indirect human evidence indicate
that exposure to elevated estrogen levels in utero may increase the risk for developing
breast cancer in adulthood (83,85).
6.0 Coronary Heart Disease in Postmenopausal Women
Coronary heart disease is the leading cause of morbidity and mortality in women
older than the age of 50 in the United States today. Traditional cardiovascular risk factors
such as hyperlipidemia, glucose intolerance, and hypertension are more clearly associated
with significant cardiovascular risk after menopause. The increased incidence of
cardiovascular events in postmenopausal women and the evidence that cardiovascular
disease on average manifests a decade later in women compared with men suggests that
estrogen deficiency may predispose women to a higher cardiovascular risk.
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Lipid profile changes after menopause include gradual increases in low-density
lipoprotein cholesterol (LDL-C) and very low-density lipoprotein cholesterol (VLDL-C),
which are thought to be secondary to the downregulation of the LDL receptors in the
liver (86-88). Additionally, high-density lipoprotein cholesterol (HDL-C) levels decrease,
and this change is a more powerful predictor of CHD mortality in postmenopausal
women (89-90). Large prospective studies, including the Framingham Heart Study,
documented a higher risk ratio of CHD in postmenopausal women with lower HDL-C
levels (90-91).
There is evidence that lipoprotein(a) [Lp(a)] is also a significant risk factor for
CHD in postmenopausal women and that HRT may have a benefit in lowering both LDL-
C and Lp(a) (92). The Lp(a) particle is structurally similar to the LDL particle and
plasminogen, and is also found in atherosclerotic lesions along injured arterial vessel
walls. There is also evidence that Lp(a) may possess both prothrombic and
proinflammatory characteristics (93,94). The Framingham Heart Study demonstrated
that increased Lp(a) levels represented an independent cardiovascular risk factor for MI
(95).
6.1 Hormone Replacement Therapy in Postmenopausal Women
Observations that the incidence of CHD events in postmenopausal women
increases dramatically compared with premenopausal years led to the hypothesis that
hormones are cardioprotective for women. It has been well documented that women with
premature menopause, induced by bilateral oophorectomy, and without simultaneous
HRT have a 2.2 times higher cardiovascular risk than premenopausal women of the same
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age (96). The Nurses' Health Study (96) demonstrated an 8-fold increase in risk of CHD
in women between the ages of 30 to 55 years with bilateral oophorectomy who did not
receive concurrent estrogen replacement therapy.
Several biologic mechanisms for HRT-induced cardioprotection have been
proposed including: improved lipid profiles, higher insulin sensitivity, and normal
vascular reactivity. Early observational trials showed a significant decrease in
cardiovascular events for women on HRT. However, recently published randomized
clinical trial results have led to uncertainty about the cardiovascular benefits of HRT.
In May 2002, the data and safety monitoring board of the Women's Health
Initiative (WHI) recommended early termination of the estrogen and progestin versus
placebo arm of the study due to an unanticipated increase in invasive breast cancer (97).
The board calculated a global risk index reflective of the relative risk of breast cancer
versus coronary heart disease (CHD), nonfatal myocardial infarction (MI), and CHD
death, along with secondary outcomes in the estrogen and progestin treated groups. This
risk index showed a disproportionately increased risk over benefit in the HRT group. As
a result, the investigators from WHI recommended that HRT should not be initiated or
continued for primary prevention in postmenopausal women. Four years earlier, the
Hormone and Estrogen Replacement Study (HERS) investigators showed no benefit of
HRT in postmenopausal women with established CHD and possibly an increased risk of
cardiovascular events within the first year of HRT administration (98). Primarily on the
basis of this study, the American Heart Association (AHA) in 2001 delivered a consensus
statement advising against starting HRT in women with a history of cardiovascular
disease (99).
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6.2 Effects of HRT during Menopause
As described above, HRT was thought to have a protective effect against CHD for
almost 2 decades. Additionally, noncoronary benefits of HRT include alleviation of
postmenopausal vasomotor symptoms, an increase in bone mineral density, and
improvement of cognitive functioning (101). Oral HRT use is reported to increase HDL-
C and to decrease LDL-C and Lp(a) by 10 to 15% (107). In the Postmenopausal
Estrogen/Progestin Interventions (PEPI) Trial, also a randomized, double-blind, placebo-
controlled study, women receiving 0.625 mg CEE had a 10 to 12% decrease in LDL over
3 years of treatment, and the addition of medroxyprogesterone acetate (MPA) or
micronized progesterone (MP) did not attenuate this effect (108). The PEPI trial assessed
the affect of various hormone regimens in postmenopausal women between the ages of
45 to 65 years. Patients treated with HRT had a 17 to 23% average drop in Lp(a) relative
to placebo (P < 0.001), which remained significant at 3 years of follow-up. This effect
was sustained in patients taking estrogen with and without concomitant progestin (108).
Recent data suggest that certain estrogen receptor polymorphisms may modify the
effect of HRT on levels of HDL-C in postmenopausal women (109). In a substudy of the
Estrogen and Replacement Atherosclerosis (ERA) trial, postmenopausal women with
CHD and the estrogen receptor-a VSl-401c/c genotype (or a closely related genotype)
had an increase in HDL subfraction 3 (HDL3) more than twice the amount observed in
women of other genotypes. These differences were observed even after adjustment for
age, race, diabetes, body mass index (BMI), and tobacco and alcohol consumption.
Additionally, these changes were evident in women receiving both estrogen alone and
estrogen with progesterone.
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In addition to the lipid lowering effects of HRT, estrogen has been reported to act
as an antioxidant (110), to decrease platelet aggregation and inhibit smooth muscle
proliferation (111), and to improve overall endothelial function (112). In animal models,
estrogen protects the endothelium and prevents myocardial dysfunction after brief
episodes of ischemia and reperfusion (113). This beneficial effect of HRT on the
endothelium is thought to be secondary to increased synthesis of NO (114), and the
antiatherogenic effect of estrogen on the endothelium has been determined to be
independent of serum lipid levels in animal models (115). Experimental animal studies
have demonstrated that estrogen treatment reduced atherosclerosis by two thirds in
injured rat aortas, and improved endothelial recovery in carotid arteries after balloon
injury (116).
Other possible mechanisms of HRT benefit in this regard include a decrease in
fibrinogen and plasminogen activating inhibitor, which increases fibrinolysis (117-118).
Plasminogen activating inhibitor was decreased by 50% when conjugated equine estrogen
(CEE) was given either alone or with progestin (118). The FINRISK Hemostasis study
demonstrated significant decreases in fibrinogen concentration in postmenopausal women
taking HRT compared with placebo (119-120). In the Atherosclerosis Risk in
Community Study, 5436 postmenopausal women without CHD were given estrogen
therapy (121). Results for the women taking estrogen versus nonestrogen users
demonstrated an improved lipid and hemostatic profile, but no changes in the carotid
intima-media thickness (117), suggesting that any reduction in cardiovascular disease in
HRT users may not entirely be due to a slowing of the progression of atherosclerotic
disease. Conversely, the Estrogen in the Prevention of Atherosclerosis Trial (EPAT), a
21
randomized, double-blind, placebo-controlled trial, showed that unopposed micronized
17P-estradiol reduced the subclinical progression of atherosclerosis regardless of the
effect on lipid levels in healthy postmenopausal women (122). In fact, the greatest
treatment benefit was observed in those women not on lipid-lowering therapy, suggesting
no synergy with lipid-lowering therapies.
Although evidence exists for an increase in blood pressure with oral contraceptive
therapy, HRT has a neutral effect on blood pressure in postmenopausal women (133).
Because HRT has lower doses of estrogen compared with oral contraceptive pills, blood
pressure is minimally affected. Reports have also described the effect of HRT on body
weight and body fat distribution as neutral or favorable (124-125). HRT may also have a
favorable benefit on insulin sensitivity (126-127). This is particularly important in the
population of women who have dyslipidemia with hyperinsulinemia and visceral obesity,
because many of these metabolic traits are typically interdependent. The Menopause
Study showed a fall in fasting blood glucose and insulin levels, as well as an
improvement in insulin reactivity after 1 year of HRT in postmenopausal women (126).
However, not all studies have shown such a beneficial affect of estrogen on insulin
sensitivity. Additionally, adding progestins to estrogen therapy may further decrease
insulin sensitivity (128).
6.3 Noncardiac Risks and Benefits to HRT
The clinician and the patient are faced with a dilemma of balancing the beneficial
effects of HRT with its possible adverse effects including breast cancer, uterine cancer,
thromboembolic disease, and gallbladder disease. HRT has been shown to increase
22
breast cancer risk for each year of use, the risk being 1.35 (95% CI, 1.21-1.49) for
women taking HRT for > 5 years (129). The primary reason for prematurely stopping
WHI in March 2002 was because of the increased incidence of invasive breast cancer
(primary adverse outcome), which exceeded safety margins in women treated with
estrogen and progestin (97). The overall hazard ratio for invasive breast cancer was 1.26
(CI, 1.00-1.59%), with the incidence increasing after 5 years. The hazard ratio was 2.13
(CI, 1.15-3.94%) for women taking prior HRT up to 5 to 10 years. The incidence of
breast cancer in a randomized secondary prevention trial (HERS II) did not demonstrate
any significant difference between treatment groups (130). The overall risk hazard with
95% CI for breast cancer in HERS and HERS II was 1.27 (95% CI, 0.84-0.94). However,
breast cancer incidence was a secondary adverse outcome and the actual number of breast
cancer deaths was only 3%, whereas lung cancer and colon cancer were 61% and 17%
respectively, of the cancer deaths.
There is new evidence that HRT may decrease the effectiveness of breast cancer
screening by mammography as a result of an increase in breast density (131). However,
no clear relation exists with the type and duration of HRT and breast density changes on
mammography. Most of the breast cancers reported with HRT use are typically less
invasive, not involving deeper breast tissue or the lymph nodes (131). Even though a
significant effect on breast cancer and subsequent mortality for postmenopausal women
using HRT is rarely reported, physicians must still advise the patient about the unwanted
effects of HRT. Other noncardiovascular risks of HRT evaluated in larger randomized
trials included biliary tract surgery, ovarian cancer, endometrial cancer, and colorectal
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Noncardiovascular benefits often considered when prescribing HRT include
decreased incidence of fracture, and improved vasomotor and cognitive functioning.
There are few randomized data available on HRT and prevention of cognitive decline or
dementia. Treatment with HRT has not, however, been shown to delay Alzheimer's
disease, even in the oldest group of women studied (135-136). Reduction of vasomotor
symptoms is an accepted indication for use of HRT in postmenopausal women. When
compared with other nonhormonal therapies such as venlafaxine, paroxetine, or
clonidine, estrogen is more effective in the treatment of hot flashes (136-137). Many
women have severe symptoms, especially after bilateral oophorectomy, and require a
higher dose estrogen regimen. Another noncardiac benefit is prevention of osteoporosis
(108,138). Women randomized to HRT have 5 to 7% more bone mass after 2 to 3 years
of treatment than women taking placebo. Until recently, no randomized trial actually
showed a reduction in osteoporotic fractures. The WHI is the first definitive trial showing
a reduction in fractures of the hip, vertebrae, and other areas (97).
7.0 Selective Estrogen ReceptorModulators (SERMs)
In 1936, Antoine Lacassagne presented a paper at the American Association for
Cancer Research that recommended estrogen as a potential target for the prevention of
breast cancer in healthy women (139). At that time, however, the target for hormone
action was unknown and there were no antagonists for estrogen action. It was not until
1962 that Jensen et al. (140) first described the estrogen receptor (ER) in estrogen-
responsive tissues, and applied this knowledge to establish a predictive test to identify
breast tumors that would respond to endocrine therapy (141). In 1958, Lerner et al.
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reported the pharmacological properties of the first nonsteroidal estrogen antagonist,
MER 25. MER 25, a complete antiestrogen with no other hormonal or antihormonal
activities, was not developed for clinical use because of low potency and unacceptable
side effects (142).
The study of the nuclear receptor superfamily has provided hope that enhanced
basic understanding can lead to new treatments in the clinic. It has long been known that
nuclear receptors play important roles in disease, including cancer, heart disease, diabetes,
obesity, and osteoporosis. A great deal of attention has been directed to the role of
steroid receptors in breast (estrogen receptor) and prostate (androgen receptor) cancer, as
well as osteoporosis. This emphasis has led to research efforts aimed at better
understanding the responses of specific tissues to the steroid receptors, as well as to
develop ligands designed to modulate those responses.
As previously discussed estrogen and estrogen/progestin have been used to delay
or reverse some of the changes related to menopause, however, epidemiologic and
clinical research have elucidated potential long-term risks associated with such therapy.
The has led to increased research aimed at developing compounds that elicit important
and tissue-specific functions of the steroid receptors without their deleterious effects. This
class of compounds has been named selective receptor modulators (SRM). The term
Selective Estrogen Receptor Modulators (SERMs) has been used to describe a group of
pharmaceuticals that manifest estrogen receptor (ER) agonist activity in some tissues, but
that oppose estrogen action in others. The SERMs are chemically diverse compounds that
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lack the steroid structure of estrogens (see Figure 4) but possess a tertiary structure that
allows them to bind to the estrogen receptor.
17p-estradiol Tamoxifene
Figure 4 - Chemical Structure of 17^-Estradiol, the Main Physiologically Relevant
Estrogen, and Three SERMs Approved by the Food and Drug Administration. 17(3-
Estradiol has a cyclophenanthrene structure, whereas tamoxifen and toremifene have a triphenylethylene
structure and raloxifene has a benzothiophene structure. Although the primary structure of these SERMs
differs strikingly from that of estrogens, they have a conformation that allows them to bind to the ligand-
binding domain of the estrogen receptor. (From Riggset al., Selective Estrogen-Receptor Modulators —
Mechanisms of Action and Application to Clinical Practice., N Engl J Med 2003 348: 618-629)
Tamoxifen was the first SERM to be used in clinically. Because of the clinical
success of tamoxifen use in breast cancer, other SERMs have been developed for use in
breast cancer. When positive effects of some SERMs were also noted in bone, further
development of second and later generations of these drugs accelerated. The operative
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concept has been to develop compounds that drive the targeted receptor to a form that
allows for tissue- and gene-specific action. The task now before us is to better define
where SERMs may be useful, how best to use them, and how to develop even more
specific compounds with important therapeutic applications.
Tamoxifen was the first drug to be classified as a SERM. Tamoxifen blocks the
binding of estradiol to the human ER and is effective in controlling the growth of ER-
positive, but not ER-negative, breast tumors (143-144). Tamoxifen was, however, found
to act as an estrogen agonist in bone and the uterus of an ovariectomized rat model (145-
147), despite having well-defined antiestrogenic/antitumor actions in the mammary gland
(148-151). Indeed, the transplantation of breast and endometrial tumors into athymic
mice treated with tamoxifen results in decreased breast cancer growth, but an increase in
endometrial cancer growth (152). To explain these findings, it was proposed that the
tamoxifen-ER complex acts as an agonist at some sites, but as an antagonist at other
select sites (150-152). Tamoxifen treatment maintains bone density in postmenopausal
women (153) and lowers circulating cholesterol concentrations (154-155). Like estrogen,
tamoxifen lowers LDL cholesterol levels and protects LDL from oxidation; but unlike
estrogen, it does not increase levels of the antiatherogenic HDL (156). The differential
action of tamoxifen on breast versus endometrial cancer growth has also been observed in
clinical trials showing reduction in the incidence of contralateral breast cancer, but an
increase in the incidence of endometrial cancer (157).
7.1 Mechanisms of Action of SERMs
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In the classic model of hormonal action, the unoccupied estrogen receptor resides
in the nucleus of the target cell in an inactive form. Binding to an agonist, such as
estradiol, alters the structure and properties of the estrogen receptor, allowing the receptor
dimer to interact with specific DNA sequences (estrogen response elements) within the
promoters of responsive genes (158). The DNA-ER complex may then regulate gene






Figure 5 - Estrogen Receptor Action. On binding an agonist or an antagonist, the estrogen
receptor (ERa or ER(3) undergoes a conformational change that permits its dimerization and facilitates the
interaction of the dimer with estrogen response elements (EREs) located within target genes. It has been
determined that estrogen facilitates the interaction of the estrogen receptor with coactivators. An
antagonist-activated estrogen receptor, on the other hand, interacts preferentially with a corepressor protein.
The binding of different SERMs to the receptor permits it to adopt conformational states distinct from that
induced by classic agonists or antagonists. The weight of available evidence suggests that the structure of
some SERM-estrogen-receptor complexes favors corepressor recruitment and that of others favors some
affinity for known coactivators. Some SERMs may also facilitate the interaction of the estrogen receptor
with yet-to-be-identified coactivators with which it would not normally couple. The implication of this
model is that SERM activity will be influenced by the relative levels of expression of the cofactors
(corepressors and coactivators) in target cells. (From Riggset et al., Selective Estrogen-Receptor
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Modulators - Mechanisms of Action and Application to Clinical Practice., N Engl J Med 2003 348: 618-
629)
recognition that tamoxifen and other SERMs have tissue-specific agonist-antagonist
activity suggested that the classic model was incomplete and that estrogen action was
more complex than had been thought (159-160).
7.1.1 Differential Estrogen-Receptor Expression in a Given Target Tissue and
Differential Estrogen Receptor Localization in Specific Cells
Target cells for estrogen action contain varying concentrations of homodimers of
one or both of two species of estrogen receptors
— ER-a and ER-(3
— as well as ER-
a/ER-P heterodimers. In addition to variable expression of the two ER isoforms in target
tissues, there is also variable localization of the ERs within a specific cell. Although
some of the effects of estrogen are mediated by intracellular ERs that act as ligand-
activated transcription factors regulating gene expression, the non-genomic effects of
estrogen (such as the rapid increase in nitric oxide release in endothelial cells) are
mediated by an ER signaling system that is localized to cell membrane caveolae (26).
Table 1 shows the target tissues and the rapid non-genomic cellular signaling pathways
activated by the two ER isoforms.
ER-a is almost always an activator, whereas ER-P can inhibit the action of ER-a
by forming a heterodimer with it (161-162). A microarray analysis in mice with deletions
ofER-a or ER-P showed that ER-P inhibited the transcription of 240 estrogen-responsive
genes by 46 percent (163). Thus, the degree of expression of these two receptor isoforms
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Receptor Rapid Action Cell Types used
ERa Ca2+ mobilization Mammary Carcinomas
Activation of ERK1 and ERK2 a. Neuroblastoma
b. Mammary carcinoma
c. Osteoblasts
d. Primary Cortical neurons
e. Cortical explants
f. Bone cell line
Activation of G proteins Ovary
Inositol phosphate production Ovary
Stimulation ofAdenylyl Cyclase Ovary, breast, uterus
Inhibition of JNK Ovary
Activation of IGF1 Kidney
Activation of PI3K Endothelium, Breast
Activation eNOS Endothelium
ActivationAkt Breast, Endothelium
ERP Activation of ERK1 and ERK2 Ovary
and Breast
Activation of JNK Ovary
Inositol phosphate production Ovary
Activation of G proteins Ovary
Stimulation ofAdenylyl Cyclase Ovary
Table 1 - Cellular signaling pathways activated by the two ER isoforms in various
target tissues (Adapted from Cato et al., Rapid Actions of Steroid Receptors in Cellular Signaling
Pathways, Sci. STKE 2002 (138) re9).
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will affect the cellular responsiveness to estrogens (164-165). Since SERMs bind to both
ER isoforms, these drugs affect the cellular responsiveness as well. Indeed, SERMs such
as raloxifene and tamoxifene function as pure antagonists when acting through ER-P but
can function as partial agonists when acting through ER-a (165).
7.1.2 Differential Estrogen-ReceptorConformation on Ligand Binding
Protein crystallography and techniques that evaluate protein surface
conformational changes have shown that binding of the ER by estradiol, tamoxifen,
raloxifene, or the pure estrogen antagonist ICI 164,384 results in a unique estrogen-
receptor conformation for each ligand (166-168). Thus, the ligand binding results in
various estrogen-receptor conformations that range from that assumed when the receptor
is bound to estrogens at one extreme to that assumed when the receptor is bound to
antiestrogens at the other extreme. Binding of SERMs to ER results in a continuum of
intermediate shapes (168-169).
7.1.3 Differential Expression and Binding to the Estrogen Receptor of Coregulator
Proteins
More than 20 coregulator proteins have been discovered that bind to estrogen
receptors and modulate their function, each acting as either a positive or a negative
transcriptional regulator (a coactivator or a corepressor, respectively) (170-173).
Depending on the unique receptor conformation induced by ligand binding, varying
combinations of coregulator proteins interact with the estrogen receptor and modulate its
function in a variety of ways. The relative and absolute levels of expression of
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coregulator proteins vary among estrogen target cells (171). In a study by Shang and
Brown (174), it was found that tamoxifen and raloxifene, which are estrogen antagonists
in the breast, act on mammary cells by recruiting corepressors to estrogen-receptor target
promoters. In contrast, tamoxifen, which is an estrogen agonist in the endometrium, acts
by recruiting coactivators to the estrogen-receptor target promoters. This recruitment
does not occur with raloxifene, which has no effect on the endometrium. It was also
found that the tamoxifen/ER-a complex activates transcription by indirectly binding to
promoters that do not contain estrogen response elements through protein-to-protein
contacts with other DNA-bound transcription factors. Moreover, the agonist effect of
tamoxifen is dependent on a higher concentration of a key coactivator, steroid receptor
coactivator- 1 (SRC-1), in the endometrial cells. Thus, variable local concentrations of
different coregulator proteins may contribute to the tissue-selective pharmacology of
SERMs.
7.2 SERMS and the Cardiovascular System
One consequence of the Women's Health Initiative findings has been an increased
interest in therapy with SERMs, because of their potential to retain most of the beneficial
effects of estrogen while avoiding most of its adverse effects. While the SERMs are
similar to conventional estrogen replacement therapy in many ways, there are also
differences with potentially important cardiovascular implications.
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7.2.1 The Effects Raloxifene on Cardiovascular Risk Factors
Raloxifene inhibits the growth of estrogen receptor-dependent mammary tumors
and reduces the occurrence of nitrosomethylurea-induced mammary tumors in rats. It has
been classified as a SERM on the basis of studies in which it prevented bone loss and
lowered serum cholesterol levels without stimulating proliferation of the endometrium
(175).
7.2.2 Raloxifene Effects on Lipoproteins and Lipids
Delmas et al. (176) studied the effect of raloxifene on serum lipids (among other
end points) in 601 postmenopausal women who were randomly assigned to receive 30,
60, or 150 mg of raloxifene or placebo daily for 24 months. Serum concentrations of total
cholesterol and LDL cholesterol decreased in all raloxifene treatment groups, whereas
serum concentrations of HDL cholesterol and triglycerides did not change.
In a study by Walsh et al. 390 postmenopausal women were enrolled in a
randomized, placebo-controlled clinical trial (177). These women were randomly
assigned to treatment with raloxifene (60 mg or 120 mg), HRT (equine estrogen 0.625 mg
and medroxyprogesterone 2.5 mg), or placebo. Lipids and coagulation factors were
measured after daily treatment for 6 months. The study showed that raloxifene favorably
alters several markers of cardiovascular risk in healthy postmenopausal women. While
many of its effects are similar to those of conventional HRT, there are also important
differences. Raloxifene lowered low-density lipoprotein cholesterol levels similarly to
estrogen. However, raloxifene lacked the potentially beneficial effects of HRT on high-
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density lipoprotein cholesterol levels and plasminogen activation inhibitor- 1, as well as
the potentially adverse effects of HRT on triglycerides and C-reactive protein. Raloxifene
also had a potentially beneficial fibrinogen-lowering effect not seen with conventional
HRT. The net effect of these differences is not clear. Proof that raloxifene reduces the risk
of heart disease must await the results of ongoing clinical trials with cardiovascular event
end points.
7.2.3 Raloxifene Effects on Atherosclerosis in Animal Models
In a study by Bjarnason et al. (179), ovariectomized rabbits treated with
raloxifene and 17P-estradiol had two-thirds and one-third, respectively, of the extent of
aortic atherosclerosis (as evaluated by the cholesterol content of the aorta) compared with
the placebo group. However, Clarkson et al. (180) treated ovariectomized cynomolgus
monkeys fed an atherogenic diet with raloxifene (1 or 5 mg/kg/day), or CEE at a dose
estimated to mimic 0.625 mg/day CEE in women, or placebo. Treatment with CEE
resulted in an approximately 70% reduction in coronary artery plaque size relative to that
in the placebo group, whereas neither the low nor the high dose of raloxifene had an
effect on coronary artery plaque size that differed from placebo-treated animals.
Although raloxifene appears to lower cholesterol content of the aorta in the study by
Bjarnason et al., this SERM may not have a considerable effect on LDL or apolipoprotein
B levels which are also known to contribute to coronary artery plaque formation.
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7.2.4 Effects of Estrogen and Raloxifene on Markers of Inflammation in
PostmenopausalWomen
When cell adhesion molecules are expressed on the surfaces of endothelial or
mononuclear cells in culture following cytokine stimulation, they are shed into the
supernatant within 24 hours. These cell adhesion molecules are also measurable in the
sera of humans. The pathophysiologic relevance of soluble cell adhesion molecules has
been suggested by their localization in atherosclerotic plaques (181), higher serum levels
in patients with atherosclerosis relative to control subjects (182), and association with
increased risk of myocardial infarction in apparently healthy (male) subjects (183). Serum
concentrations of E-selectin, ICAM-1, and VCAM-1 were reported to be higher in
postmenopausal women with coronary artery disease who were not taking HRT than
those taking HRT at the time of cardiac catheterization (184). In a study of
hypercholesterolemic postmenopausal women Koh et al. (185) reported that CEE
significantly reduced circulating levels of the cell adhesion molecules E-selectin, ICAM-
1, and VCAM-1 relative to respective pretreatment values, with the greatest effect noted
on E-selectin, the cell adhesion molecule specific to the activated endothelium.
Blum et al. (186) conducted a randomized, double-blind, three-period crossover
treatment trial to examine whether raloxifene versus CEE reduces serum levels of
inflammatory markers in 23 postmenopausal women. Levels of C-reactive protein
(CRP), a marker of increased cardiovascular risk, were increased by 50% with CEE, but
were unchanged with raloxifene versus placebo values. Levels of interleukin-6 (IL-6), a
cytokine implicated in atherosclerosis that also conveys increased risk, were
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nonsignificantly increased with CEE and raloxifene relative to placebo. Levels of matrix
metalloproteinase-9 (MMP-9) (an enzyme secreted by macrophages and activated smooth
muscle cells and implicated in plaque rupture) were increased by 30% with CEE relative
to placebo, but not with raloxifene. Serum E-selectin levels were reduced by both CEE
and raloxifene compared with placebo, with CEE having a greater effect than raloxifene.
Both therapies equally reduced serum ICAM-1 levels compared to placebo. Serum
VCAM-1 was reduced with CEE, but raloxifene did not have an effect on VCAM-1 when
compared with placebo. Thus, raloxifene lowers circulating levels of some cell adhesion
molecules to a lesser extent than CEE in otherwise healthy postmenopausal women, but
does not increase other markers of inflammation as seen with CEE therapy (CRP,
interleukin-6, and MMP-9). The biologic relevance of these differences in effects on
markers of inflammation remains to be determined in clinical trials.
The ultimate goal of SERM research is the discovery of a tissue-selective drug
that has all the beneficial effects of estrogen and has none of its adverse effects as shown
in Figure 6. The present study was undertaken to evaluate a panel of novel SERMs with
regard to their effects on vascular endothelial and breast cancer cells. In collaboration
with Eli Lilly pharmaceuticals, we received 10 potential SERMs for which we
established dose response curves for proliferation of immortalized vascular endothelial
cells (EA.hy926) and human breast cancer cells (MCF-7). We also evaluated the rapid
induction of eNOS activation in the EA.hy926 endothelial cells. This cell line has been
used in the Bender lab and has been reported (187) to express a 46-kDa protein that
immunoreacts with selective ER-alpha Abs and is capable of tranducing E2-triggered
rapid signaling. EA.hy926 cells phenotypically represent fully differentiated vascular
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ECs that exclusively express ER46 under our culture conditions. These cells are highly
responsive to membrane-impermeant E2 within minutes, as demonstrated by NO release
and cGMP production through an E2-stimulated, ligand-dependent PI3-
kinase/Akt/endothelial NO synthase (eNOS) pathway (188,189). In addition, we
examined the effects of this group of SERMs on MCF-7 breast cancer cell apoptosis.







Lowering of circulating cholesterol




Prevention of breast cancer
— Reduction in risk of
endometrial cancer
Prevention of osteoporosis
Figure 6 — The Ideal SERM. Estrogen is associated with decreases in osteoporosis, and there are
unconfirmed beneficial effects with estrogen in preventing Alzheimer's disease and coronary heart disease.
The principal positive action of estrogen is to alleviate menopausal symptoms and mood changes. The
negative actions of estrogen are an increased risk of breast or endometrial cancer. An ideal SERM would
enhance the benefits of estrogen but would prevent breast and endometrial cancers. In the latter case,
progestin therapy would be unnecessary, and periodic menstrual bleeding would be avoided. Raloxifene
possesses this property. To date, tamoxifen has been shown to decrease breast cancer risk, and raloxifene
has been shown to reduce the risk of fractures. Neither tamoxifen nor raloxifene fulfills the criteria for an
ideal SERM, but continuing clinical evaluation will establish the long-term safety of the SERM concept.
(From Craig et al., Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer,
Osteoporosis, and Coronary Heart Disease, J Natl Cancer Inst (2001); 93: 1449-1457.
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1.0 Material and Methods
1.1 Materials
Stock solutions of LY compounds (provided by Lilly Pharmaceuticals) were
prepared in DMSO with final DMSO concentrations less than 0.1%. 176-estradiol was
purchased from Sigma. The anti-eNOS antibody was purchased from Transduction
Laboratories. Anti-phosphorylated Akt (pAKT) and anti-Akt antibodies were purchased
from Cell Signaling. The anti-phosphorylated eNOS (peNOS) antibody was from New
England Biolabs. Secondary antibodies, anti-rabbit horseradish peroxidase and anti-
mouse horseradish peroxidase, were purchased from Santa Cruz Biotechnology Inc.,
Santa Cruz, CA. The CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay
was purchased from Promega. Rainbow molecular weight markers were purchased from
Amersham Pharmacia.
1.2 Cell lines and culture conditions
Breast adenocarcinoma MCF-7 cells (Michigan Cancer Foundation, Detroit, MI)
were propagated in phenol-free M199 medium supplemented with 10% gelding horse
serum (GHS) (<1.0 pg/mL estradiol), insulin (lOug/ml), L-Glutamate 2mM, penicillin
lOOU/ml and streptomycin lOOju.g/m.1. The cell line was passaged in phenol-free Ml 99
medium, subcultured every 6 days with a split ratio of approximately 1:10, and growth
medium was changed every 2 days. Before E2 or LY stimulation, cells were cultured in
"E2-free medium" which consisted of phenol-free M199 with 0.5% GHS, L-Glutamate
2mM, penicillin lOOU/ml, and streptomycin lOOjtig/ml. "Starvation medium" consisted
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of phenol-free M199 with L-Glutamate 2mM, penicillin lOOU/ml, streptomycin
lOO/xg/ml and BSA 0.25%.
The permanently established EA.hy926 endothelial cell (EC) line (200) was
provided by CJS Edgell (University of North Carolina). Cells were maintained in
DMEM, which was supplemented with 10% FBS, 5 mmol/L hypoxanthine, 0.8 mmol/L
thymidine, 20 jtimol/L aminopterin, L-Glutamate 2mM, penicillin lOOU/ml and
streptomycin lOOpig/ml. Before E2 stimulation, cells were cultured in "E2-free deprivation
medium", which consisted of phenol-free DMEM with gelding horse serum (<1.0 pg/mL
estradiol), L-Glutamate 2mM, penicillin lOOU/ml, streptomycin 100/ig/ml. "Starvation
medium" consisted of phenol-free DMEM, L-Glutamate 2mM, penicillin lOOU/ml,
streptomycin 100-ig/ml and BSA 0.25%.
1.3 MCF-7 Cell Proliferation Assay
MCF-7 cells cultured in C-100 Petri dishes were harvested using 0.25% trypsin
when approximately 85% confluent. MCF-7 cells were resuspended in culture media and
seeded in 96-well microtiter plates, at a concentration of 8000 cells/well in a volume of
0.2ml of culture media. The cells were incubated at 37°C for 24hrs before the culture
media was aspirated from the wells. The cells were washed twice with CMF-PBS, and
0.2ml of "E2-free deprivation medium" were added followed by incubation at 37°C for
48hrs. The cells were then washed again twice with CMF-PBS and 0.2ml of "starvation
medium" was added for 12hrs. After the starvation period the various cell treatments
were prepared in "E2-free deprivation medium" and added to the appropriate wells. The
cells were incubated at 37°C for 48hrs before measurements were made.
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Working concentrations of compounds LY1-11 were prepared the day of the
experiment in 100% ETOH as dilutions from concentrated stocks in DMSO maintained at
-80 C. Solvent controls had the same concentration of ETOH and were added to all the
experiments.
Dose response curves for the 11 potential SERM compounds were established
using the CellTiter 96® AQueoUs Non-Radioactive Cell Proliferation Assay (Promega).
This is a calorimetric method for determining the number of viable cells in proliferation
assays. The CellTiter 96® AQue0us Assay is composed of solutions of a tetrazolium
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine
methosulfate) PMS. MTS is bioreduced by cells into a formazan product that is soluble
in tissue culture medium. The absorbance of the formazan product is measured directly
from 96-well assay plates without additional processing. The conversion of MTS into the
aqueous soluble formazan product is accomplished by dehydrogenase enzymes found in
metabolically active cells. The quantity of formazan product, as measured by absorbance
at 490nm, is directly proportional to the number of living cells in culture. The 96-well
microtiter plates were read on a microtiter plate reader (Molecular Devices Ltd., Crawley,
West Essex, United Kingdom).
1.4 Endothelial Cell Proliferation Assay
EA.hy926 ECs cultured in C-100 Petri dishes were harvested when confluent.
ECs were resuspended in "E2-free deprivation medium" and seeded in 96-well microtiter
plates, at a concentration of 8000 cells/well in a volume of 0.2ml of culture media. The
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cells were incubated at 37°C for 48hrs before the culture medium was aspirated from the
wells. The cells were washed twice with CMF-PBS and 0.2ml of "E2-free deprivation
medium" added followed by incubation at 37°C for 48hrs. The cells were then washed
again twice with CMF-PBS and 0.2ml of "starvation medium" added for a 12hr
starvation period. After the starvation period the various LY treatments for the cells were
prepared in "E2-free deprivation medium" and added to the appropriate wells. The cells
were incubated at 37°C for 48hrs before measurements were made using the CellTiter
96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega).
1.5 MCF-7 Cell Cycle Progression Assay
MCF-7 cells propagated in "E2-free deprivation medium" in C-100 Petri dishes
were used when approximately 75% confluent. The plates were washed with CMF-PBS
and 8ml/plate of starvation media added, followed by incubation at 37°C for 12hrs. After
the starvation period the various cell treatments were prepared in starvation media and
added to the appropriate plates. The cells were incubated at 37 C for 48hrs.
Preparation of Cells for Fixation and Cell Cycle Analysis
The plates were washed three times with CMF-PBS and trypsinized. The cells
were then resuspended in 0.750ml ACCUMAX™ (cell detachment reagent), transferred
to 1.5ml eppendorf tubes and incubated at 37°C for 15 min. The tubes were then spun at
8000rpm for 3 min and the supernatant aspirated. The cell pellet was resuspended with
0.5ml cold 70% ETOH and incubated at -20°C for one hour. The cells were spun at
8000rpm for 3 min and the supernatant aspirated. The cell pellet was resuspended in
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ACCUMAX™ and incubated at 37°C for 10 min. The cells were then spun again at
8000rpm for 3 min and the supernatant aspirated. The cell pellet was resuspended in
0.2ml of staining buffer (20/ig/ml propidium iodide, 0.05% Triton X-100, 200/xg/ml
RNase in CMF-PBS) and placed on ice for 45 min. 1ml of washing buffer (1%BSA,
0.03% NaN3 in CMF-PBS) was then added and the cells were spun at 8000rpm for 3 min
and the supernatant aspirated. Finally, the cells were resuspended in 0.5ml of FACS
assay buffer (1% formaldehyde, 1% BSA in CMF-PBS). DNA content of 10,000
events(cells)/treatment was analyzed using a FACSCalibur™ flow cytometer (Becton
Dickinson) and the CellQuest software version provided by the manufacturer.
1.6 Western Blot Analysis
Cells were lysed as follows. Cell monolayers were washed twice in ice-cold
phosphate-buffered saline then scraped into ice-cold lysis buffer (in mmol/L) Tris-HC120
(pH 7.4), EDTA 2.4, Triton X-100 1%, sodium deoxycholate 1%, SDS 0.1%, NaCl 100,
NaF 10, Na3V04 1, NaPiP04 1, and protease inhibitor cocktail (Roche).). The lysates were
incubated for 5 min on ice, and cellular debris was cleared by centrifugation (15,000g,
5 min, 4 °C). Equal amounts of total protein were separated by SDS-PAGE then
transferred to nitrocellulose. Proteins were visualized using enhanced chemiluminescence
after incubation (overnight at 4 °C for primary and 1 hr at room temperature for
secondary antibodies) using the following primary antibodies: Anti-eNOS, Anti-
phosphorylated eNOS, Anti-phosphorylated Akt and anti-Akt. Immunoblots were probed
with species-specific secondary antibodies coupled to horseradish peroxidase before
visualized by enhanced chemiluminescence.
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Results
The results below (1-4) are those of the LY compounds that were chosen based on
the results of the cell proliferation screening assays performed on EA.hy926 endothelial
cells and the MCF-7 breast cancer cells. The results of the initial screening assays
revealed general patterns amongst the compounds in terms of their effects on endothelial
and epithelial cell proliferation that are represented by the four chosen compounds. These
four compounds were used to further examine the effects on MCF-7 cell cycle analysis,
and to evaluate endothelial cell p-Akt and p-eNOS expression using western blot analysis.
1.0 Results for compound LY5
1.1 EA.hy926 Cell Proliferation Assay
Stimulation of endothelial cells with LY5 showed a bell-shaped curve of efficacy,
with a decreasing stimulatory effect at the highest concentration tested. Treatment with
LY5 10"12M resulted in cell proliferation comparable to control. Higher concentrations of
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EAhy 48hr Cell Proliferation Assay
U
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Figure 1 - Cell proliferation Assay with EA.hy926 endothelial cells. Multi-well dishes
plated in triplicate, 8000 cells/well. The cells were estrogen deprived for 48 hours, followed by a 12 hour
starvation period before stimulation with LY 5 at the concentrations indicated above. The plates were read
48 hours after stimulation.
compared to control as shown in Figure 1. Further increase in LY5 concentration to 10"
6M resulted in a decrease in cell proliferation down to a level similar with control, and at
LY5 10 5M there is a precipitous drop in cell proliferation, with no viable cells present
after 48hrs, suggesting that LY5 may have a toxic or an anti-estrogenic effect at higher
concentrations.
1.2 MCF-7 Cell Proliferation Assay
Treatment with LY5 resulted in a bell-shaped curve of efficacy, with a peak level
of cell proliferation observed at 10"UM. Stimulation with LY5 10"12M resulted in a 40%
decrease in cell proliferation compared to control, however, stimulation with LY5 10""
produced a 2-fold increase in cell proliferation when compared to the lower concentration.
Stimulation with LY5 10~nM and 10"10M also resulted in cell proliferation approximately
1.2 fold above the level seen with control. Further increases in LY5 concentration
inhibited cell proliferation compared with control, with a 40% decrease for LY5 at 10"6M,
44
suggesting an anti-estrogenic effect on MCF-7 cells at these higher concentrations.
Stimulation of MCF-7 cells with LY5 10"5M resulted in a 70% drop in cell proliferation
compared to control which may suggest a toxic effect in addition to an anti-estrogenic
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Figure 2
- Cell proliferation Assay with MCF-7 breast cancer cells. Multi-well dishes
plated in triplicate, 8000 cells/well. There was a 12 hour starvation period before stimulation with LY5 at
the concentrations indicated above. The plates were read 48 hours after stimulation.
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1.3 MCF-7 Cell Cycle Analysis For Estrogen and Insulin
MCF-7 cells cultured in prolonged estrogen deprived media, were serum starved
for 12 hours followed by a stimulation period. The optimal conditions for MCF-7 cell
cycle analysis were established and it was found that the greatest percentage of cells in S
and G2/M phases were achieved after 48 hours of stimulation with insulin or estrogen as
shown in Figure 3 below. The optimal estrogen concentration for stimulation was 1
ng/ml as shown by the 2-fold increase in S phase population and the 2.5-fold increase in
G2/M phase population of MCF-7 cells, as shown in Figure3. As expected, estrogen and
insulin confer a significant protective advantage against apoptosis compared with control

















D 1- Veh control
■ 2-E2 1.0ng/ml
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- MCF-7 Cell Cycle Analysis. MCF-7 cells cultured in prolonged estrogen deprivation
were serum starved for 12 hours and stimulated with insulin (20/ig/ml) and varying concentrations of
estrogen.
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(190), as shown by the 70% decrease in the percentage of apoptotic cells during cell cycle
analysis. The protective effect against apoptosis does not appear to depend on the
concentration of estrogen used to stimulate the breast cancer cells in the range of
concentrations examined in the above experiment (1 to lOOng/ml).
1.3.1 MCF-7 Cell Cycle Analysis for LY5
Cell cycle analysis was performed on MCF-7 cells stimulated with estrogen
and/or LY5. LY5 10~I2M resulted in a four-fold increase in the population of apoptotic
cells, a 40% decrease in the Gl/GO phase and a no significant change in the population of
S and G2/M phase cells when compared to estrogen. This suggests that LY5 decreases
the survival of breast cancer cells as evident by the decrease in the Gl/GO population and
the increase in apoptotic cells when compared to estrogen. LY5 10" M resulted in a
similar increase in the population of apoptotic cells compared to LY5 10"12M, however,
there was also a 20% decrease in the population of S and G2/M phase cells when
compared to estrogen and LY5 10"12M. This suggests that LY5 10"6M acts to decrease
the survival of MCF-7 cells (perhaps due to an increase in apoptosis), but also acts to
decrease the percentage of cells progressing to the S and G2 phases of the cell cycle, as
compared to estrogen. LY 5 10"9M caused a significant decrease in the percentage of
apoptotic cells, when compared to the higher and lower concentrations of LY5 (10"12M
and 10"6M). Thus, the results ofMCF-7 cell cycle analysis are consistent with the results
for the MCF-7 cell proliferation assays, which produced a bell-shaped curve in response
to increasing concentrations of LY5. LY5 10" M resulted in an increase in apoptotic
cells during cell cycle analysis, reflected by a decreased cell numbers observed in the cell
proliferation assay. LY5 10"9M resulted
in a decrease in apoptotic cells during cell cycle
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analysis, reflected by an increase in cell numbers observed in the cell proliferation
analysis. LY5 10"6M resulted in an increase in the population of apoptotic cells in
addition to a decrease in the percentage of cells in the S and G2/M phases, reflected by a
decrease in cell numbers in the cell proliferation assay.





































































- MCF-7 Cell Cycle Analysis. MCF-7 cells cultured in prolonged estrogen deprivation
were serum starved for 12 hours and stimulated with estrogen and/or LY5 as shown above.
The addition of LY5 10"12M to the estrogen treatment results in a two-fold
increase in MCF-7 apoptosis, compared to estrogen alone. The addition of LY5 10"9M to
the estrogen treatment results in no significant change in the level of apoptosis, however,
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there is a slight increase in the S and G2/M phases compared to estrogen alone. Estrogen
in combination with LY5 10"6M resulted in a three-fold increase in the percentage of cells
undergoing apoptosis and a 20% decrease in the S and G2/M phases (similar to LY5 10"
M alone) when compared to estrogen alone. The results are shown in Figure 4.
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Figure 5
- MCF-7 Cell Cycle Analysis. Stimulation with A. control, B. InM estrogen
9M and D. LY5 109M + ElnM.
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1.4 EA.hy926 Rapid Stimulation with Estrogen and LY5
1.4.1 Induction of Akt phosphorylation by LY5
In order to evaluate the effect of LY5 on the phosphorylation of Akt in EA.hy926
ECs, cultured cells were stimulated with LY5 and or estrogen. Stimulation of EA.hy926
cells with LY5 resulted in a slightly higher level of phosphorylated-Akt (p-Akt) higher
compared to estrogen. The combination of LY5 and estrogen resulted in an actual
decrease in the level of p-Akt as shown below.
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Figure 6 - Phosphorylation of Akt by LY5 and Estrogen in Endothelial Cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LY5 and/or estrogen as shown above
for 10 minutes at 37°C. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, probed with
anti-pAkt antibody, and reprobed with anti-Akt antibody.
1.4.2 Induction of eNOS phosphorylation by LY5
In order to evaluate the effect of LY5 on the phosphorylation of eNOS in EA.hy926 ECs,
cultured cells were stimulated with LY5 and or estrogen. Stimulation of EA.hy926 cells
with estrogen resulted in a greater level of phosphorylated-eNOS (p-eNOS) compared to
LY5. The addition of LY5 to estrogen did not result in a significant change in the level of
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Figure 7 - Phosphorylation of eNOS by LY5 and estrogen in endothelial cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LY5 and/or estrogen as shown in figure
A for 10 minutes at 37°C. A. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, probed
with antiphospho eNOS antibody, and reprobed with anti-eNOS antibody.
1.5 Summary of Results for LY5
The results of the cell proliferation assay and cell cycle analysis for MCF-7 cells
reveal a bell-shaped dose response to LY5, with a ICso-value of approximately 10"6M. At
the lowest concentration tested (10"12M) it appears that LY5 decreases survival ofMCF-7
cells compared to estrogen. At higher concentrations (10"6M) LY5 appears to decrease
the survival and also decrease the progression of MCF-7 cells through the cell cycle to
the S and G2 phases when compared to estrogen. At intermediate concentrations of LY5,
however, there is increased survival of MCF-7 cells, but not to the extent seen with
estrogen.
The results of the cell proliferation assay for the endothelial cells show increased
cell proliferation above control for LY5 between the concentrations 10"nM and 10"7M.
There is minimal cell proliferation at 10"12M and 10"6M, and at higher concentrations (10"
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M) there is a significant decrease in viable cells, most likely due to a cytotoxic effect on
the cells at that concentration.
Stimulation of endothelial cells to evaluate the effects on the rapid
phosphorylation of Akt and eNOS, showed that estrogen caused an increase in both p-Akt
and p-eNOS as expected since p-Akt directly phosphorylates and activates eNOS (189).
Stimulation with LY5 10"12M, however, resulted in an increase in p-Akt but not a
significant increase in the levels of p-eNOS, suggesting that LY5 may cause
downregulation of eNOS, independent of Akt activation, for example through inhibition
of the MAP kinase pathway of eNOS activation.
At a concentration of 10"6M, LY5 exhibits an overall favorable profile with
respect to its effects on the breast cancer cell line. LY5 decreased MCF-7 cell
proliferation, decreased cell survival, decreased progression to the S and G2/M phases of
the cell cycle. Additionally, these effects were not reversible in the presence of estrogen.
Although there was an overall favorable effect on endothelial cell proliferation, we did
not observe a significant increase in p-eNOS activity after treatment with LY5.
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2.0 Results for compound LY7
2.1 MCF-7 Cell Proliferation Assay for LY7
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- Cell proliferation Assay with MCF-7 breast cancer cells. Multi-well dishes
plated in triplicate, 8000 cells/well. 12 hour starvation period before stimulation with LY 7 at the
concentrations indicated above. The plates were read 48 hours after stimulation.
Treatment ofMCF-7 cells with LY7 for 48hrs showed an overall inhibitory effect
on cell proliferation. There was a dose dependent inhibitory effect on cell proliferation,
with a statistically significant reduction in cell numbers starting at a concentration of 10"
55
M. Cell numbers were approximately in the same range as the control treatment for LY7
at 10" M and dropped off by 50% at LY7 10"5M, suggesting an overall anti-estrogenic
effect for LY7 on MCF-7 cells in the range of concentrations examined.
2.2 EA.hy926 Cell Proliferation Assay for LY7














Solvent 1E-12 1E-11 1E-10 1E-09 1E-08 1E-07 1E-06 1E-05
Control
LY7 concentration (M)
EAhy 48hr Cell Proliferation Assay




- Cell proliferation Assay with EA.hy926 endothelial cells. Multi-well dishes
plated in triplicate, 8000 cells/well. The cells were estrogen deprived for 48 hours, followed by a 12 hour
starvation period before stimulation with LY 7 at the concentrations indicated above. The plates were read
48 hours after stimulation.
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Treatment of endothelial cells with LY7 resulted in an overall increase in cell
proliferation when compared to vehicle treatment. At 10'12M there was a 70% increase in
cell numbers compared to control, however, increasing concentrations of LY7 resulted in
a subsequent decrease in a cell proliferation. At 10"5M cell proliferation was at the level
of that observed with the control treatment. These results suggest that at low
concentrations LY7 exerts an overall estrogenic effect on endothelial cell proliferation,
but at increasing concentrations the kinetics of LY7 shift to an anti-estrogenic profile.
2.3 MCF-7 Cell Cycle Analysis for LY7
The results of cell cycle analysis performed on MCF-7 cells stimulated with
estrogen and or LY7 are shown in Figure 10. At 10"12M LY7 produced a four-fold
increase in the population of apoptotic cells, in addition to a 40% decrease in the S
andG2/M phases, compared to estrogen. This suggests that at this concentration LY7
reduces breast cancer cell progression to the S and G2/M phases and also reduces
survival as evident by the increase in apoptosis. At higher concentrations, LY7 10"6M
caused a three-fold increase in apoptosis, and a 15% decrease in the S and G2/M phases
when compared to the estrogen treatment. The addition of LY7 10"12M or LY7 10"6M to
the estrogen treatment resulted in a two fold increase in apoptosis, but no significant
changes in the S and G2/M phases when compared to estrogen treatment alone,
suggesting that LY7 partially antagonizes the survival benefit of estrogen on MCF-7 cells,
but does not significantly antagonize the positive effect of estrogen on cell cycle
progression.
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Figure 10 - MCF-7 Cell Cycle Analysis. MCF-7 cells cultured in prolonged estrogen deprivation
were serum starved for 12 hours and stimulated with estrogen and/or LY7 as shown above.
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- MCF-7 Cell Cycle Analysis Stimulation with A. control, B.LY7 10"12M C. InM
estrogen and D. LY7 10"12M + ElnM.
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2.4 EA.hy926 Rapid Stimulation with Estrogen and LY7
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Figure 12
- Phosphorylation of Akt by LY7 and estrogen in endothelial cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LY7 and/or estrogen as shown in A. for
10 minutes at 37°C. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, probed with
antiphospho Akt antibody, and reprobed with anti-Akt antibody.
In order to evaluate the effect of LY7 on the phosphorylation of Akt in EA.hy926
ECs, cultured cells were stimulated with LY7 and/or estrogen. Treatment of EA.hy926
cells with LY7 at 10" M and 10" M resulted in no significant increase in phosphorylated-
Akt (p-Akt) compared to estrogen. The addition of LY7 10"12M to estrogen did not result
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in a significant change in the level of p-Akt, however, when 10"6M of LY7 was added to
the estrogen treatment there was a 40% reduction in the level of p-Akt, suggesting that at
this concentration LY7 antagonizes the positive effect of estrogen on the induction of Akt
phosphorylation, and subsequently phosphorylation and activation of eNOS.
2.4.2 Induction of eNOS Phosphorylation by LY7
In order to evaluate the effect of LY7 on the phosphorylation of eNOS in
EA.hy926 ECs, cultured cells were stimulated with LY7 and or estrogen. Incubation of
EA.hy926 cells with LY7 at either concentration did not result in a significant increase in
the level of phosphorylated-eNOS (p-eNOS) compared to control. The addition of LY7
10" M or 10" M to estrogen resulted in a 35% and 25% decrease respectively in the level
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Figure 13 - Phosphorylation of eNOS by LY7 and estrogen in endothelial cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LY7 and/or estrogen as shown in figure
A for 10 minutes at 37°C. A. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, probed
with antiphospho eNOS antibody, and reprobed with anti-eNOS antibody. B. Densitometric analysis of p-
eNOS/eNOS
2.5 Summary of Results for LY7
The results of the cell proliferation assay for the EA.hy926 cells show that LY7
stimulates endothelial cell proliferation. This effect on cell proliferation is more
pronounced at the lower concentrations examined and progressively diminishes as the
concentration increases. It appears that there is a differential effect of low or high
dosages of the compound, with the lower doses causing an increase in endothelial cell
proliferation. Higher doses, however, are associated with a negative effect on cell
proliferation. This suggests that there may be an optimal concentration at which LY7
may exert full estrogen-like activity, whereas at higher concentrations it may have partial
antiestrogenic effects. A similar differential effect of low or high dosages was reported
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by Simoncini et al with the experimental SERM aclobifene on eNOS activity in aortas of
estrogen deficient rats (25).
The cell proliferation assay for the MCF-7 cells show that LY7 exhibits an overall
inhibitory effect on cell proliferation, which is dose dependent and most pronounced at
10" M. Cell cycle analysis of MCF-7 cells showed a significant decrease in the survival
of breast cancer cells, but also a decrease in the progression to the S and G2/M phases
most pronounced at 10"12M of LY7.
Stimulation of endothelial cells to evaluate the effects on the rapid
phosphorylation of Akt and eNOS showed no significant effect on the levels of p-Akt or
p-eNOS for the two concentrations of LY7 examined. Addition of LY7 to estrogen
actually resulted in a decrease in the levels of p-eNOS compared to estrogen alone,
suggesting an anti-estrogenic effect of LY7 under these conditions.
At a concentration of 10"12M, LY7 exhibits a favorable profile with respect to its
effects on the breast cancer cell line. LY7 decreased MCF-7 cell proliferation, decreased
cell survival, and decreased progression to the S and G2/M phases of the cell cycle.
Additionally, these effects were not reversible in the presence of estrogen. Although
there was an overall favorable effect on endothelial cell proliferation, we did not observe
a significant increase in p-eNOS activity after treatment with LY7.
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3.0 Results for compound LY8











EAhy 48hr Cell Proliferation Assay
l.llllll


















EAhy 48hr Cell Proliferation Assay




- Cell proliferation Assay with EA.hy926 endothelial cells. Multi-well dishes
plated in triplicate, 8000 cells/well.
The cells were estrogen deprived for 48 hours, followed by a 12 hour
starvation period before stimulation with LY 8 at the concentrations indicated above. The plates were read
48 hours after stimulation.
Treatment of endothelial cells with LY8 for 48hrs showed an overall increase in
cell proliferation above that seen with the control treatment. The response appears to be
65
dose dependent, with a peak in cell proliferation seen at LY8 10"8M. Further increase in
LY8 concentration appears to exert an inhibitory effect on cell proliferation.
3.2 MCF-7 Cell Proliferation Assay
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Figure 16
- Cell proliferation Assay with MCF-7 breast cancer cells. Multi-well dishes
plated in triplicate, 8000
cells/well. There was a 12 hour starvation period before stimulation with LY 8 at
the concentrations indicated above. The plates were read 48 hours after stimulation.
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Stimulation of MCF-7 cells with LY8 resulted in lower levels of cell proliferation
compared to control for concentrations below 10"9M. There was a slight increase in cell
numbers compared to control for concentrations of LY8 greater than 10"9M.
3.3 MCF-7 Cell Cycle Analysis
Cell cycle analysis was performed on MCF-7 cells stimulated with estrogen and
or LY8. At LY8 10" M there was a four-fold increase in the level of apoptosis, and there
was a 20% decrease in the population of cells found in the S and G2/M phases,
c
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- MCF-7 Cell Cycle Analysis. MCF-7 cells cultured in prolonged estrogen deprivation
were serum starved for 12 hours and stimulated with estrogen and/or LY8 as shown above.
when compared to estrogen. Treatment with 10"6M of LY8 did not cause a significant
change in the distribution
of cells undergoing apoptosis or progressing to the S and G2M
phases. At this concentration (10"6M) it is possible that LY8 exerts an effect on MCF-7
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cells that is similar to estrogen. Although MCF-7 cell treatment with LY8 alone appears
to exert an anti-estrogenic effect at 10"12M, the addition of estrogen to the LY8 10 12M
treatment seems to override this effect. One possible mechanism for this is that estrogen
has a higher affinity for the estrogen receptor, displacing LY8 and diminishing its effect.









































































Figure 18 - MCF-7 Cell Cycle Analysis Stimulation with A. control, B.LY8 10"12M C. LY8 10"
6M, D estrogen 10"9M, E. LY8 10"12M + Estrogen 10"9M, F. LY8 10"6M + Estrogen 10"9M
3.4 EA.hy926 Rapid Stimulation with Estrogen and LY8
3.4.1 Induction ofAkt phosphorylation by LY8
In order to evaluate the effect of LY8 on the phosphorylation of Akt in EA.hy926
ECs, cultured cells were stimulated with LY8 and/or estrogen. Stimulation of EA.hy926
cells with LY8 at 10"6M resulted in comparable levels of phosphorylated-Akt (p-Akt)
compared to estrogen. LY8 10"12M resulted in a slightly higher level of p-Akt compared
to estrogen alone. The addition of LY8 to the estrogen treatment resulted in a decrease in
the level of p-Akt compared to the estrogen treatment alone, suggesting an antagonistic
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Figure 19 - Phosphorylation of Akt by LY8 and estrogen in endothelial cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LY8 and/or estrogen as shown in A. for
10 minutes at 37°C. A. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, probed with
antiphospho Akt antibody, and reprobed with anti-Akt antibody. B. Densitometric analysis of pAkt/Akt
levels after stimulation with estrogen and/or LY8
3.4.2 Induction of eNOS Phosphorylation by LY8
In order to evaluate the effect of LY8 on the phosphorylation of eNOS in
EA.hy926 ECs, cultured cells were stimulated with LY8 and/or estrogen. Incubation of
EA.hy926 cells with LY8 10"'2M did not result in a significant increase in the level of
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phosphorylated-eNOS (p-eNOS) compared to control. The addition of LY8 10-12M to
estrogen resulted in an increase in the level of p-eNOS compared to estrogen alone,
suggesting a synergistic effect of LY8 with estrogen. At LY8 10"6M actually resulted in
a 50% decrease in p-eNOS levels, suggesting an anti-estrogenic effect at this
concentration. At 10"6M LY8 also decreased the ability of estrogen to induce eNOS
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- Phosphorylation of eNOS by LY8 and estrogen in endothelial cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LY8 and/or estrogen as shown in figure
A for 10 minutes at 37°C. A. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, probed
with antiphospho eNOS antibody, and reprobed with anti-eNOS antibody. B. Densitometric analysis of p-
eNOS/eNOS after stimulation with estrogen and/or LY8.
71
3.5 Summary of Results for LY8
The results of the cell proliferation assay for the EA.hy926 cells show that LY8
stimulates endothelial cell proliferation. There is peak cell proliferation at 10-8M, with
lower levels of proliferation at higher and lower concentrations of LY8.
MCF-7 cell showed a dose dependent increase in cell proliferation in response to
LY8, with peak proliferation occurring at levels just above those seen in the control
group. Cell cycle analysis of MCF-7 cells showed a significant decrease in the survival
of breast cancer cells, but also a decrease in the progression to the S and G2/M phases
when stimulated with 10"12M of LY8. This effect MCF-7 cells disappeared in the
presence of estrogen.
Stimulation of endothelial cells to evaluate the effects on the rapid
phosphorylation of Akt and eNOS showed that LY8 alone induced Akt phosphorylation
at levels similar to those seen with estrogen. However, LY8 resulted in a decrease of p-
eNOS levels compared to estrogen alone, and in combination with estrogen resulted in
lower levels of e-NOS phosphorylation.
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4.0 Results for compound LY11
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Figure 21
- Cell proliferation Assay with EA.hy926 endothelial cells. Multi-well dishes
plated in triplicate, 8000 cells/well. The cells were estrogen deprived for 48 hours, followed by a 12 hour
starvation period before stimulation with LY 1 1 at the concentrations indicated above. The plates were
read 48 hours after stimulation.
Treatment of endothelial cells with LY11 resulted in increased proliferation for
the concentration range between 10"12M and 10"6M. There was a 60% increase in cell
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proliferation for LYll at 10"12 compared to control treatment. The degree of cell
proliferation decreased with increasing dose of LY1 1, but was still 30% higher for LY1 1
10 M compared to control. There was a precipitous drop in cell proliferation, however,
for LY10" M at a level 50% lower compared to the control treatment. This may represent
the concentration at which LY1 1 exerts an overall toxic effect on endothelial cells.
4.2 MCF-7 Cell Proliferation Assay for LYll
Treatment ofMCF-7 cells with LY1 1 for 48hrs resulted in an overall inhibitory effect on
cell proliferation. Cell numbers were at similar levels as control for concentrations of
LYll smaller than 10"UM. At higher concentrations there was a dose dependent
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Figure 22 - Cell proliferation Assay with MCF-7 breast cancer cells. Multi-well dishes
plated in triplicate, 8000 cells/well. There was a 12 hour starvation period before stimulation with LY 1 1 at
the concentrations indicated above. The plates were read 48 hours after stimulation.
4.3 MCF-7 Cell Cycle Analysis for LYll
Cell cycle analysis was performed on MCF-7 cells stimulated with estrogen and
or LY1 1. Treatment with LY1 1 10"12M resulted in a four-fold increase in the percentage
of apoptotic cells, and a 25% decrease in S and G2/M phase populations, compared to
estrogen. The addition of LYll 10"12M to estrogen resulted in a two-fold increase in
apoptosis, but no significant decrease in the population of cells in the S and G2/M phases,
suggesting that at this concentration LYll decreases the survival benefit conferred by
estrogen on the breast cancer cells,
with no significant change in cell cycle progression.
Treatment with LYll 10"6M resulted in a five-fold increase in apoptosis and a 30%
decrease in cell cycle progression to the S and G2/M phases.
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Figure 23 - MCF-7 Cell Cycle Analysis. MCF-7 cells cultured in prolonged estrogen deprivation
were serum starved for 12 hours and stimulated with estrogen and/or LYl 1 as shown above.
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Figure 24 - MCF-7 Cell Cycle Analysis. Stimulation with A. control, B.LYll 10"12M C.
estrogen 10"9M and D. LY7 10",2M + Estrogen 10'9M
4.4 EA.hy926 Rapid Stimulation with Estrogen and LYll
4.4.1 Induction of Akt phosphorylation by LYll
In order to evaluate the effect of LYll on the phosphorylation of Akt in
EA.hy926 ECs, cultured cells were stimulated with LYll and/or estrogen. Stimulation
of EA.hy926 cells with LYl 1 at 10"12M resulted in a comparable level of phosphorylated-
Akt (p-Akt) compared to estrogen, and LYll
10"6M treatment resulted in a 1.6 fold
increase of p-Akt compared to control. The addition of LYll to the estrogen did not
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- Phosphorylation of Akt by LYll and estrogen in endothelial cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LYll and/or estrogen as shown in A.
for 10 minutes at 37°C. A. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose, probed
with antiphospho Akt antibody, and reprobed with anti-Akt antibody. B. Densitometric analysis of
pAktMkt after stimulation with estrogen and LYl 1.
4.4.2 Induction of eNOS phosphorylation by LYll
In order to evaluate the effect of LYll on the phosphorylation of eNOS in
EA.hy926 ECs, cultured cells were stimulated with LYl 1 and or estrogen. Incubation of
EA.hy926 cells with LYll 10"12M did not result in a significant increase in the level of
phosphorylated-eNOS (p-eNOS) compared to control. LYll 10"6M actually resulted in a
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significant decrease in p-eNOS. The addition of LYll 10"12M or 10"6M to estrogen
resulted in a two-fold decrease in the level of p-eNOS compared to estrogen alone.
eNOS
1. Control
2. LYll 10 12M
3.LY111012M+E2
4. LYll 10 6M
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- Phosphorylation of eNOS by LYll and Estrogen in Endothelial cells.
Confluent monolayers of EA.hy.926 cells underwent estrogen deprivation for 48 hours, followed by a 12
hour starvation period. The cells were subsequently incubated with LYll and/or estrogen as shown in
figure A for 10 minutes
at 37°C. A. Lysates were subjected to SDS-PAGE, transferred to nitrocellulose,
probed with antiphospho
eNOS antibody, and reprobed with anti-eNOS antibody. B. Densitometric
analysis of p-eNOS/eNOS after stimulation with estrogen and LYl 1.
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Summary of Results for LYll
The results of the cell proliferation assay show that LYll causes an increase in
cell proliferation in endothelial cells at concentrations lower than 10"6M. LYll caused a
dose dependent inhibition of MCF-7 cell proliferation.
The results of the cell cycle analysis show that LYll caused a decrease in
survival and a decrease in cell cycle progression, which was most pronounced at 10"6M.
LYll was also shown to antagonize the cell survival benefit that estrogen exhibits on
MCF-7 cells.
Stimulation of endothelial cells to evaluate the effects on the rapid
phosphorylation of Akt and eNOS showed that although LYll exerted a positive effect
on the induction of Akt phosphorylation at levels similar to those seen with estrogen,
there was a negative effect on p-eNOS levels compared to estrogen alone. The
combination of LYll with estrogen also resulted in lower levels of e-NOS
phosphorylation compared to estrogen alone.
At a concentration of 10"6M, LYll exhibits an overall favorable profile with
respect to its effects on the breast cancer cell line. LYll decreased MCF-7 cell
proliferation, decreased cell survival, and decreased progression to the S and G2/M
phases of the cell cycle better than any of the other compounds examined. Although
there was an overall favorable effect on endothelial cell proliferation, we did not observe
a significant increase in p-eNOS activity after treatment with LYl 1.
Discussion
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Cardiovascular disease is a major concern for postmenopausal women, and
estrogen deficiency represents an important factor in the pathophysiology of coronary
heart disease. The value of postmenopausal therapy with estrogen or estrogen/progestin
in the prevention and treatment of menopause-related symptoms and accelerated bone
loss is well established. Observational studies have demonstrated that HRT users have a
reduced risk of age-associated diseases or conditions such as osteoporosis, cardiovascular
disease, and Alzheimer's disease. Recent randomized controlled trials, however, have
found that HRT has actually been associated with serious adverse events on the
cardiovascular system in both primary and secondary cardiovascular disease prevention
studies. Thus, the use of HRT has remained limited. Additionally, adherence is poor, with
the overwhelming majority of women discontinuing treatment because of the fears of
cancer of the breast or uterus, unwanted bleeding, and other side effects.
The development of compounds that act as estrogens selectively on the desired
tissues has major clinical significance. One of the required goals for an ideal molecule is
that the positive effects of estrogens on the cardiovascular system
not be lost. SERMs
bind with high affinity to the ERbut have tissue-specific effects distinct from estradiol.
They act as estrogen agonists
in some tissues and estrogen antagonist in others. The
development of SERMs that selectively
interact with specific receptors and specific
coactivators and corepressors in specific organ systems offers the possibility of improving
the risk/benefit profile relative to HRT and perhaps even extending the use of these
compounds to men.
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Although approved SERMs such as tamoxifen and raloxifene have potential
clinical utility in breast cancer and osteoporosis prevention, widespread use in risk
reduction for breast cancer and osteoporosis is limited by an increased risk of adverse
events or side effects. Disadvantages of tamoxifen include an increased risk of
endometrial cancer and venous thromboembolic disease, as well as hot flashes. Even
though raloxifene does not increase the risk of endometrial cancer like tamoxifen, it
increases the risk of hot flashes and venous thromboembolic disease, and its
cardiovascular and cognitive effects are uncertain.
Ideally, a SERM would have to provide superior efficacy in the treatment and
prevention of breast cancer relative to tamoxifen, with an improvement in the toxicity
profile. The ideal SERM should also be effective in the prevention and treatment of
osteoporosis. Certainly, a property of an ideal SERM would be to provide beneficial
effects for the cardiovascular system in women with and without preexisting coronary
heart disease. Since molecular and animal research have shown a beneficial effect of
estrogen on nerve cells, further desirable effects of the ideal SERM would be to maintain
or improve cognitive function and delay or, if possible, prevent the development of
dementia. Current SERMs increase or induce hot flashes and therefore cannot be used to
treat menopausal symptoms. A property of an ideal SERM would be to provide relief
from menopausal symptoms and, certainly, not to exacerbate these symptoms.
The molecular mechanisms for the tissue-specific effects of SERMs involve a
unique interplay between the two types of estrogen receptors, ER-a and ER-p, and a
series of coactivator and corepressor proteins. Because of this complexity the effect of
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SERMs on the profile of tissue-specific events is still unpredictable. The objective of this
study is to identify novel SERMs that have the initial potential to exert the vascular
protective effects of estradiol, without exhibiting unfavorable pro-proliferative effects on
mammary epithelial cells.
The effects of estrogen on the cardiovascular system are pleiotropic, but many of
the beneficial effects are exerted through actions on vascular cells (19,191). Endothelial
cells affect the homeostasis of the vessel wall in terms of vasomotor tone, platelet and
monocyte adhesion, growth of smooth muscle cells, and extracellular matrix production
and thereby provide an antithrombotic and anti-inflammatory barrier for the normal
vessel wall. Disruption of the anatomic and functional integrity of the endothelium has
been postulated as a mechanism for the initiation of atherosclerosis (192). Experiments
by Krasinski et al. and White et al. have suggested that after arterial injury, acceleration
of reendothelialization by 176-estradiol is associated with attenuation of intimal
hyperplasia (61,193). It has also been suggested that increased endothelial cell turnover
mediated through accelerated apoptosis induced by TNF-a plays a role in endothelial
disruption (70). A study by Alvarez et al. demonstrated a protective effect of 17(3-
estradiol against TNF-a mediated apoptosis in cultured endothelial cells, suggesting that
estradiol may help migrating cells to colonize an injured vessel and aid in
reendothelialization.
Accordingly, we chose to use a cell proliferation assay as a screening tool to
identify compounds that stimulate endothelial cell proliferation. At the same time we
also chose to identify compounds that inhibit or at least do not stimulate MCF-7 breast
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cancer cell proliferation, since the importance of estrogen in the regulation of breast
cancer cell proliferation has been demonstrated both in vitro and in vivo (197). The
clinical efficacy of oophorectomy and pharmacological agents that inhibit the synthesis
or action of estrogen further emphasize the importance of estrogen induced mitogenesis
in breast cancer (198).
These initial screening tests allowed us to identify 4 compounds that exhibited
both a favorable increase in endothelial cell proliferation and a favorable decrease in
breast cancer cell proliferation. The four compounds chosen for further experiments
(LY5, LY7, LY8 and LYll) all caused an overall increase in endothelial cell
proliferation. LY5, however, caused a rather significant drop in cell numbers at the
highest concentration tested (10"5M). The fact that there were no viable cells present
after 48hrs of exposure to LY5 suggests a toxic effect on endothelial cells at
concentrations in the 10"5M range. (With an anti-estrogenic effect one might expect a
more gradual decrease in cell numbers with increasing concentrations of the compound.)
This toxic effect, of course, may render the compound unsafe for therapeutic purposes.
The results of the MCF-7 cell proliferation assays revealed favorable profiles for
compounds LY7 and LYll. These two compounds did not cause stimulation of MCF-7
proliferation above that observed with control for
the concentration range tested, which is
a very important property for
a SERM to exhibit. LYl 1 also has a more potent inhibitory
effect on the breast cancer cell line compared to LY7. Although both LY5 and LY8 exert
an inhibitory effect on MCF-7 proliferation, this effect is not consistent along the entire
range of concentrations
examined. Unfortunately, the increase in cell proliferation
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observed above control from some of the concentrations render these compounds less
than ideal as potential SERMs.
In order to further evaluate the effect of the selected potential SERMs on the
breast cancer cell line, cell cycle analysis was performed. In order to prevent or treat
breast cancer we expect the ideal SERM to cause a decrease in MCF-7 survival and a
decrease in progression to the S and G2/M phases of the cell cycle. At both
concentrations tested compound LYl 1 shows the most favorable results, with an increase
in the percentage of cancer cells undergoing cell death, and a decrease in the number of
cancer cells progressing through the cell cycle. LYll also inhibits the survival benefit
that estrogen has on the breast cancer cell line, and decreases the percentage of cells
progressing through the cell cycle. LY7 exhibits a profile similar to LYll, but is less
effective at slowing cell cycle progression at the higher of the two concentrations tested.
Although both LY5 and LY8 are able to increase the percentage of cancer cells
undergoing apoptosis and decrease the number of cancer cells progressing through the
cell cycle, these benefits are not consistent for all the concentrations examined. These
results are consistent with the results of the MCF-7 cell proliferation assays, and show
that these compounds have an estrogenic effect at some concentrations, but act as an anti
estrogen at other concentrations.
This suggests that there may be an optimal
concentration at which LY5 and LY8 may exert full estrogen-like activity, whereas at
other concentrations it may have partial antiestrogenic effects. This characteristic of
compounds LY5 and LY8 limits their potential use as a therapeutic agent since they
appear to have
the potential to function both as an estrogen and an anti-estrogen on breast
epithelial cells depending on the
concentration. A similar differential effect of low or
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high dosages was reported by Simoncini et al (25) with the experimental SERM
aclobifene on eNOS activity in aortas of estrogen deficient rats, as noted in the Results
section.
Nitric oxide (NO) synthesized by endothelial cells is a potent anti-inflammatory
and antiatherogenic factor that is able to prevent endothelial cell dysfunction.
Furthermore, NO is of principal importance for the regulation of vascular tone, and for
the control of hemostasis (194). Estrogen stimulates the synthesis and release of NO
through the regulation of both transcriptional and non transcriptional eNOS activity
(25,189,195,196). Rapid NO synthesis upon exposure to estrogen relies on nongenomic
activation ofMAPK and PI3K/Akt pathways (25,195,196). For this reason, we evaluated
the effects of the selected compounds on the rapid induction of Akt and eNOS
phosphorylation, and hence the rapid production of NO. The optimal SERM would be
expected to stimulate the rapid synthesis and release of NO at levels similar to estrogen.
Unfortunately, the compounds tested did not induce phosphorylation of e-NOS at levels
observed with stimulation by estrogen. It should be noted, however, that the LY doses
used to test for induction of NO synthesis were chosen based on the results from the cell
proliferation assays and the cell cycle analysis experiments. It is possible that these
compounds may exhibit a more favorable profile in terms of NO induction at
concentrations other than the ones examined in theses experiments.
According to the results of this study, LYll appears to have the most favorable
profile of the compounds examined.
LY 1 1 treatment results in increased endothelial cell
proliferation for concentrations
lower or equal to 10"6M. LYll exerts concentration
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dependent growth inhibition of MCF-7 breast cancer cells with an ICso-value of
approximately 10"6M, close to the IC50-value of 0.9xlO"6M of tamoxifen (199). These
findings are also consistent with the results of the cell cycle analysis for MCF-7 cells that
showed LYll causeds a significant decrease in survival of breast cancer cells, as
evidenced by the increase in apoptosis. It also causes a significant decrease in the
progression of the cell cycle to the S and G2/M phases, as compared to estrogen. LYll
also appears to antagonize the survival benefit conferred by estrogen on the breast cancer
cells, as evidenced by the increase in apoptosis when the two treatment are combined.
In summary, the present study has demonstrated a potentially beneficial vascular
effect of a novel SERM, while acting as an estrogen antagonist and an inhibitor of growth
and survival in the breast cancer cell line MCF-7. As the molecular mechanisms of the
action of SERMs become more completely understood, rational drug design will replace
the current empirical method for the discovery of new SERMs. It is very likely that the
ultimate goal of SERM research will be achieved, that is, the discovery of a tissue-
selective drug that has all the beneficial effects of estrogen, including superagonist
protective actions on the cardiovascular and skeletal systems, has none of its adverse
effects, and offers protection against breast cancer. Even more exciting may be the
possibility that the plasticity of estrogen action exhibited by
SERMs will also be found to
be a general feature of the steroid nuclear-receptor family of molecules.
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